3/24
03:02 pm
cntx
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
3/24
09:50 am
cntx
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
Low
Report
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
3/24
09:17 am
cntx
Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.
Medium
Report
Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.
3/23
05:09 pm
cntx
Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]
Medium
Report
Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]
3/23
04:24 pm
cntx
Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]
Medium
Report
Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]
3/23
04:16 pm
cntx
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Medium
Report
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
3/21
01:31 am
cntx
Low
Report
3/19
07:30 am
cntx
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Low
Report
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
3/14
11:41 am
cntx
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data [Yahoo! Finance]
Medium
Report
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data [Yahoo! Finance]
3/8
04:16 pm
cntx
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference [Yahoo! Finance]
Medium
Report
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference [Yahoo! Finance]
2/28
01:30 am
cntx
Low
Report
2/24
06:47 am
cntx
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
High
Report
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
2/16
01:08 am
cntx
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
Low
Report
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
2/9
08:06 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/9
07:30 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences
2/8
02:05 am
cntx
Context Therapeutics (NASDAQ:CNTX) was downgraded by analysts at
Wall St
Medium
Report
Context Therapeutics (NASDAQ:CNTX) was downgraded by analysts at
Wall St
1/31
01:33 am
cntx
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
Medium
Report
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
1/18
06:11 am
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/16
04:05 pm
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)